Global Pharmacogenetics Testing in PsychiatryDepression Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143178
- Pages: 225
-
Format:
Short Description
Global Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing, and Chromosomal Array-Based Tests), Patient Type (Childrens, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, and Software & Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution Hospital Pharmacy, and Others), Countries (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Austria, Lithuania, Ireland, Norway, Poland and Rest of the Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Vietnam, Philippines, Indonesia and Rest of the Asia-Pacific, UAE, Israel, South Africa, Egypt, Kuwait and Rest of the Middle East and Africa, Brazil, Argentina, Peru, and Rest of the South America) - Industry Trends and Forecast to 2029
Market Definition
Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.
Pharmacogenetics testing studies the interaction between the drug and the gene response of a person and searches for the gene variation, which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights which subsequently be used to develop customized or personalized medication.
Market Segmentation
The global pharmacogenetics testing in psychiatry/depression market is categorized into seven notable segments, which are the type, test type, product type, gene type, patient type, end user, and distribution channel.
On the basis of type, the global pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders
On the basis of test type, the global pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests
On the basis of patient type, the global pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatric
On the basis of product type, the global pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services
On the basis of gene type, the global pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others
On the basis of end user, the global pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others
On the basis of distribution channel, the global pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third-party distribution hospital pharmacy, and others
Market Players
Some of the major players operating in the global pharmacogenetics testing in psychiatry/depression market are:
Genelex (Part of Invitae corporation)
Genewiz (Part of Azenta Life Sciences)
MD Lab
BiogeneiQ, Inc.
ONEOME, LLC
Myriad Genetics, Inc.
GenXys
Castle Biosciences, Inc.
PacBio
QIAGEN
Thermo Fisher Scientific Inc.
AB BIOTICS.S.A.
Coriell Life Sciences
Eurofins Scientific
Illumina, Inc.
Dynamic DNA Laboratories
STADAPHARM GmbH
Color Health, Inc.
Cnsdose
Genomind, Inc.
Healthspek
myDNA Life Australia Pty Ltd.
HudsonAlpha
Sonic Healthcare Limited
TABLE OF CONTENTS
1 INTRODUCTION 64
1.1 OBJECTIVES OF THE STUDY 64
1.2 MARKET DEFINITION 64
1.3 OVERVIEW OF GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 64
1.4 CURRENCY AND PRICING 66
1.5 LIMITATIONS 67
1.6 MARKETS COVERED 67
2 MARKET SEGMENTATION 71
2.1 MARKETS COVERED 71
2.2 GEOGRAPHICAL SCOPE 72
2.3 YEARS CONSIDERED FOR THE STUDY 73
2.4 DBMR TRIPOD DATA VALIDATION MODEL 74
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 77
2.6 MULTIVARIATE MODELLING 78
2.7 MARKET APPLICATION COVERAGE GRID 79
2.8 SOURCE LIFELINE CURVE 79
2.9 DBMR MARKET POSITION GRID 81
2.10 VENDOR SHARE ANALYSIS 82
2.11 SECONDARY SOURCES 83
2.12 ASSUMPTIONS 83
3 EXECUTIVE SUMMARY 84
3.1 PESTEL ANALYSIS 90
3.2 PORTER'S FIVE FORCES MODEL 91
3.3 INDUSTRIAL INSIGHTS: 92
3.4 PIPELINE ANALYSIS FOR GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 94
3.5 EPIDEMIOLOGY 95
4 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS 96
4.1 UNITED STATES (U.S.) 96
4.1.1 ROLE OF FDA 96
4.1.2 ROLE OF CDC AND HCFA 96
4.2 EUROPEAN UNION (EU) 97
4.3 FRANCE 97
4.4 AUSTRALIA 97
4.5 SOUTH KOREA 97
5 MARKET OVERVIEW 98
5.1 DRIVERS 100
5.1.1 INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER 100
5.1.2 RISE IN HEALTHCARE EXPENDITURE 100
5.1.3 RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE 101
5.2 RESTRAINTS 101
5.2.1 LACK OF SKILLED MEDICAL AND GENOMIC EXPERT 101
5.2.2 LACK OF STRONG CLINICAL EVIDENCE 102
5.2.3 HIGH COST ASSOCIATED WITH THE DIAGNOSIS 102
5.3 OPPORTUNITIES 102
5.3.1 RISING ADVANCEMENTS IN TECHNOLOGY 102
5.3.2 INCREASING NUMBER OF KEY PLAYERS IN MARKET 103
5.4 CHALLENGES 103
5.4.1 STRICT GOVERNMENT REGULATION ON NEW PRODUCTS AND INSTRUMENTS APPROVAL 103
5.4.2 DEARTH OF SKILLED PERSONNEL 104
6 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 105
6.1 OVERVIEW 106
6.2 ANXIETY 109
6.3 DEPRESSION 109
6.4 MOOD DISORDERS 110
6.5 BIPOLAR DISORDERS 111
6.6 EATING DISORDERS 112
6.7 PSYCHOTIC DISORDERS 112
7 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT 114
7.1 OVERVIEW 115
7.2 CONSUMABLES 118
7.2.1 WHOLE GENOME SEQUENCING KITS 119
7.2.2 CHROMOSOMAL ARRAY BASED KITS 119
7.3 INSTRUMENTS 120
7.4 SOFTWARE AND SERVICES 120
8 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE 122
8.1 OVERVIEW 123
8.2 WHOLE GENOME SEQUENCING 126
8.2.1 EXOME SEQUENCING 127
8.2.1.1 SNP 128
8.2.1.2 CNV 128
8.2.1.3 RARE PTV MUTATION 128
8.2.1.4 ULTRA PTV MUTATION 128
8.2.1.5 OTHERS 128
8.2.2 KARYOTYPE 128
8.2.2.1 SNP 129
8.2.2.2 CNV 129
8.2.2.3 RARE PTV MUTATION 129
8.2.2.4 ULTRA PTV MUTATION 129
8.2.2.5 OTHERS 129
8.2.3 LOW COVERAGE WGS 129
8.2.3.1 SNP 130
8.2.3.2 CNV 130
8.2.3.3 RARE PTV MUTATION 130
8.2.3.4 ULTRA PTV MUTATION 130
8.2.3.5 OTHERS 130
8.2.4 DEEP COVERAGE WGS 130
8.2.4.1 SNP 131
8.2.4.2 CNV 131
8.2.4.3 RARE PTV MUTATION 131
8.2.4.4 ULTRA PTV MUTATION 131
8.2.4.5 OTHERS 131
8.2.5 MICROARRAY 131
8.2.5.1 SNP 132
8.2.5.2 CNV 132
8.2.5.3 RARE PTV MUTATION 132
8.2.5.4 ULTRA PTV MUTATION 132
8.2.5.5 OTHERS 132
8.2.6 OTHERS 132
8.3 CHROMOSOMAL ARRAY BASED TESTS 132
8.3.1 MICRODELETIONS 133
8.3.2 MICRO DUPLICATIONS 133
9 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE 134
9.1 OVERVIEW 135
9.2 CYP2C19 138
9.3 CYP2C9 AND VKORC1 138
9.4 CYP2D6 139
9.5 HLA-B 140
9.6 HTR2A/C 140
9.7 HLA-A 141
9.8 CYP3A4 142
9.9 SLC6A4 142
9.10 MTHFR 143
9.11 COMT 144
9.12 OTHERS 144
10 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE 146
10.1 OVERVIEW 147
10.2 ADULT 150
10.3 GERIATRIC 150
10.4 CHILD 151
11 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET , BY END USER 152
11.1 OVERVIEW 153
11.2 HOSPITAL AND CLINICS 156
11.2.1 DRUG EFFECTIVENESS 157
11.2.2 SIDE EFFECTS 157
11.2.3 DOSAGE 157
11.3 DIAGNOSTICS LABORATORIES 157
11.3.1 DRUG EFFECTIVENESS 158
11.3.2 SIDE EFFECTS 158
11.3.3 DOSAGE 158
11.4 ACADEMIC AND RESEARCH INSTITUTES 158
11.4.1 DRUG EFFECTIVENESS 159
11.4.2 SIDE EFFECTS 159
11.4.3 DOSAGE 159
11.5 OTHERS 159
12 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 161
12.1 OVERVIEW 162
12.2 DIRECT TENDER 165
12.3 THIRD PARTY DISTRIBUTION 165
12.4 HOSPITAL PHARMACY 166
12.5 OTHERS 166
13 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION 168
13.1 OVERVIEW 169
13.2 NORTH AMERICA 175
13.2.1 U.S. 187
13.2.2 CANADA 194
13.2.3 MEXICO 201
13.3 EUROPE 208
13.3.1 GERMANY 220
13.3.2 FRANCE 227
13.3.3 U.K. 234
13.3.4 ITALY 241
13.3.5 RUSSIA 248
13.3.6 SPAIN 255
13.3.7 TURKEY 262
13.3.8 NETHERLANDS 269
13.3.9 SWITZERLAND 276
13.3.10 POLAND 283
13.3.11 HUNGARY 290
13.3.12 AUSTRIA 297
13.3.13 NORWAY 304
13.3.14 IRELAND 311
13.3.15 LITHUANIA 318
13.3.16 REST OF EUROPE 325
13.4 ASIA-PACIFIC 326
13.4.1 JAPAN 338
13.4.2 CHINA 345
13.4.3 SOUTH KOREA 352
13.4.4 INDIA 359
13.4.5 AUSTRALIA 366
13.4.6 SINGAPORE 373
13.4.7 THAILAND 380
13.4.8 MALAYSIA 387
13.4.9 INDONESIA 394
13.4.10 PHILIPPINES 401
13.4.11 VIETNAM 408
13.4.12 REST OF ASIA-PACIFIC 415
13.5 SOUTH AMERICA 416
13.5.1 BRAZIL 428
13.5.2 ARGENTINA 435
13.5.3 PERU 442
13.5.4 REST OF SOUTH AMERICA 449
13.6 MIDDLE EAST AND AFRICA 450
13.6.1 SOUTH AFRICA 462
13.6.2 SAUDI ARABIA 469
13.6.3 U.A.E 476
13.6.4 ISRAEL 483
13.6.5 EGYPT 490
13.6.6 REST OF MIDDLE EAST AND AFRICA 497
14 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 498
14.1 COMPANY SHARE ANALYSIS: GLOBAL 498
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 499
14.3 COMPANY SHARE ANALYSIS: EUROPE 500
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 501
15 SWOT ANALYSIS 502
16 COMPANY PROFILE 503
16.1 THERMO FISHER SCIENTIFIC INC. 503
16.1.1 COMPANY SNAPSHOT 503
16.1.2 RECENT FINANCIALS 503
16.1.3 COMPANY SHARE ANALYSIS 504
16.1.4 PRODUCT PORTFOLIO 504
16.1.5 RECENT DEVELOPMENT 505
16.2 ILLUMINA, INC. 506
16.2.1 COMPANY SNAPSHOT 506
16.2.2 REVENUE ANALYSIS 506
16.2.3 COMPANY SHARE ANALYSIS 507
16.2.4 PRODUCT PORTFOLIO 507
16.2.5 RECENT DEVELOPMENTS 508
16.3 MYRIAD GENETICS, INC. 510
16.3.1 COMPANY SNAPSHOT 510
16.3.2 COMPANY SHARE ANALYSIS 510
16.3.3 PRODUCT PORTFOLIO 511
16.3.4 RECENT DEVELOPMENT 511
16.4 SONIC HEALTHCARE LIMITED 512
16.4.1 COMPANY SNAPSHOT 512
16.4.2 REVENUE ANALYSIS 512
16.4.3 COMPANY SHARE ANALYSIS 513
16.4.4 PRODUCT PORTFOLIO 513
16.4.5 RECENT DEVELOPMENTS 513
16.5 QIAGEN 514
16.5.1 COMPANY SNAPSHOT 514
16.5.2 RECENT FINANCIALS 514
16.5.3 COMPANY SHARE ANALYSIS 515
16.5.4 PRODUCT PORTFOLIO 515
16.5.5 RECENT DEVELOPMENTS 516
16.6 EUROFINS SCIENTIFIC 517
16.6.1 COMPANY SNAPSHOT 517
16.6.2 REVENUE ANALYSIS 517
16.6.3 PRODUCT PORTFOLIO 518
16.6.4 RECENT DEVELOPMENT 518
16.7 AB-BIOTICS, S.A. 519
16.7.1 COMPANY SNAPSHOT 519
16.7.2 PRODUCT PORTFOLIO 519
16.7.3 RECENT DEVELOPMENTS 519
16.8 BIOGENIQ INC. 521
16.8.1 COMPANY SNAPSHOT 521
16.8.2 PRODUCT PORTFOLIO 521
16.8.3 RECENT DEVELOPMENT 521
16.9 CASTLE BIOSCIENCE, INC. 522
16.9.1 COMPANY SNAPSHOT 522
16.9.2 REVENUE ANALYSIS 522
16.9.3 PRODUCT PORTFOLIO 523
16.9.4 RECENT DEVELOPMENT 523
16.10 CNSDOSE 524
16.10.1 COMPANY SNAPSHOT 524
16.10.2 PRODUCT PORTFOLIO 524
16.10.3 RECENT DEVELOPMENT 524
16.11 COLOR HEALTH, INC. 525
16.11.1 COMPANY SNAPSHOT 525
16.11.2 PRODUCT PORTFOLIO 525
16.11.3 RECENT DEVELOPMENTS 526
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
